AstraZeneca Drug Reduces Death Risk by 42% in Advanced Gastric Cancer Trial

Phase III clinical trial results for AstraZeneca's sonesitatug vedotin (Sone-Ve), an antibody-drug conjugate, showed a 42% reduction in death risk for previously treated patients with Claudin 18.2-positive advanced gastric and gastroesophageal junction cancers. This finding marks a significant advance, potentially expanding targeted therapy options for these gastrointestinal cancers.